Contact Us
Drug Search Results
More Filters [+]

Cefiderocol

Alternative Names: cefiderocol, s-649266, fetroja
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Cefiderocol (CFDC), a novel siderophore cephalosporin possessed unique drug delivery systems and stability to beta-lactamases, has the potential to become first-line therapy for most aggressive MDR Gram-negative pathogens infection. (Sourced from: https://www.frontiersin.org/articles/10.3389/fmed.2021.741940/full)

Mechanisms of Action: PBP Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Slovakia | Spain | Sweden | United Kingdom | United States

Approved Indications: Gram-Negative Bacterial Infections | Urinary Tract Infections | Nephritis | Pyelonephritis

Known Adverse Events: Headache | Candidiasis | Hypokalemia | Constipation | Diarrhea

Company: Shionogi
Company Location: OSAKA M0 541-0045
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cefiderocol

Countries in Clinic: Australia, Belgium, Estonia, Georgia, Greece, Hungary, Latvia, Lithuania, Malaysia, Mexico, Panama, Philippines, Russia, Singapore, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Communicable Diseases|Gram-Negative Bacterial Infections|Intraabdominal Infections|Pneumonia|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Sepsis|Urinary Tract Infections

Phase 1: Acute Kidney Injury|Healthy Volunteers|Pyelonephritis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
QPEX-400

P1

Recruiting

Pneumonia, Ventilator-Associated|Pyelonephritis|Pneumonia, Bacterial|Urinary Tract Infections

2025-12-01

1904R2136

P2

Recruiting

Communicable Diseases|Gram-Negative Bacterial Infections

2024-12-31

24%
HHC-2022-0045

P1

Completed

Acute Kidney Injury

2024-11-20

1704R2133

P2

Completed

Pneumonia, Bacterial|Urinary Tract Infections|Communicable Diseases|Gram-Negative Bacterial Infections

2024-09-17

Recent News Events

Date

Type

Title

09/04/2024

News Article

 Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentations from Its Expanding Product Portfolio at IDWeek 2024

05/30/2024

News Article

 Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex's Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections

04/26/2024

News Article

 Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

09/27/2023

News Article

 Venatorx Pharmaceuticals to Present at IDWeek 2023

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions